[A23-88] Migalastat (Fabry disease) – Benefit assessment according to §35a Social Code Book V
Last updated 15.02.2024
Project no.:
A23-88
Commission:
Commission awarded on 15.08.2023 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Digestion, metabolism and hormones
Adults and adolescents aged 12 years and older with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency) and who have an amenable mutation
Added benefit not proven
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
https://dx.doi.org/10.60584/A23-88
| Project no. | Title | Status |
|---|---|---|
| G16-04 | Migalastat - Assessment according to § 35a (para. 1, sentence 10) Social Code Book V | Commission completed |
| G21-25 | Migalastat (Fabry disease) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V | Commission completed |
| A24-10 | Migalastat (Fabry disease) – Addendum to Commission A23-88 | Commission completed |
Federal Joint Committee (G-BA)
2024-02-15 A G-BA decision was published.